Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 1.88%, with notable gains from constituent stocks such as MicroPort Medical (00853) up 8.63%, and Stone Pharmaceutical Group (01093) up 7.40% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 3.00%, marking its third consecutive increase, with a latest price of 1.34 HKD and a weekly cumulative increase of 8.89% [1] - The trading volume for the Hang Seng Biotechnology ETF was active, with a turnover of 34.45% and a transaction value of 161 million HKD, indicating strong market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, growing by 2 million shares over the past week, ranking in the top third among comparable funds [2] - The ETF has seen continuous net inflows over the last three days, with a peak single-day net inflow of 3.83 million HKD, totaling 8.73 million HKD in net inflows [2] Group 3 - Over the past year, the net value of the Hang Seng Biotechnology ETF has increased by 130.59%, ranking 3rd out of 122 QDII equity funds, placing it in the top 2.46% [3] - WuXi Biologics announced the construction of a modular biomanufacturing facility in Singapore, which is part of a strategic collaboration with Pharmadule Morimatsu [3] - The latest report from Zhongyin Securities suggests focusing on three main lines: 1) sectors with stable growth such as medical devices and pharmaceuticals, 2) the CXO sector and medical equipment expected to see a turnaround, and 3) innovative fields related to national medical insurance negotiations [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is highlighted as the only ETF tracking the Hang Seng Biotechnology Index to have received net inflows this year, with the lowest management fee of 0.15% per year among Hong Kong pharmaceutical ETFs [4]

Group 1: Market Performance - The Hong Kong stock market saw all three major indices decline in the morning session, with the Hang Seng Tech Index dropping 1.57%, marking a five-day losing streak [1] - The Hang Seng Index and the Hang Seng China Enterprises Index both fell by 0.43% [1] - Internet healthcare stocks performed strongly, with Ping An Good Doctor surging 9% to reach a new high [1] Group 2: ETF Performance - The Hang Seng Medical ETF (513060) experienced significant fluctuations, rising over 3% during the session with a trading volume nearing 2.5 billion yuan and a turnover rate exceeding 30% [1] - Most constituent stocks within the ETF saw gains, including Ping An Good Doctor up over 11%, MicroPort Medical up over 8%, and several others with gains exceeding 4% [1] Group 3: Policy Developments - The National Healthcare Security Administration (NHSA) held four seminars in July 2025 to discuss a comprehensive policy support system for innovative drugs and medical devices [2][3] - The first seminar focused on establishing a scientific value evaluation system for innovative products, which is expected to enhance the efficiency of healthcare resource allocation [2] - Subsequent seminars addressed collaborative innovation among various stakeholders, the empowerment of research and development through healthcare data, and the identification of pain points in drug development [3] Group 4: Policy Implementation - Recent procurement policy optimizations by the NHSA have improved market access for innovative drugs and medical devices, allowing medical institutions to report quantities by brand and ensuring fair competition [4] - A new pricing mechanism for newly listed drugs has been established, allowing innovative drugs with breakthrough efficacy to secure reasonable premium pricing [4] Group 5: Industry Trends - The policy changes are reshaping the pharmaceutical industry's innovation logic, encouraging differentiation in innovation and directing capital towards unmet clinical needs [5] - The internationalization of Chinese innovative drugs is accelerating, with significant increases in licensing transactions and overseas revenue for companies like BeiGene and Innovent Biologics [5] - The ability to leverage healthcare data for post-market research is becoming a competitive advantage for companies [5] Group 6: High-End Medical Equipment - The government is supporting the development of high-end medical devices, setting a target for 70% of county-level hospitals to use domestically produced equipment by 2025 [6] - The new medical infrastructure is expected to drive over 200 billion yuan in equipment procurement demand [6] Group 7: Investment Opportunities - The Hang Seng Medical ETF (513060) is positioned to benefit from the policy dividends and industry upgrades, focusing on innovative drug and medical device companies [7] - The ETF's constituent companies are expected to experience significant growth as the government supports high-end medical equipment and innovative drug development [7][8]

于7月29日根据股份购买协议拟以每股对价股份12港元的发行价格，根据一般授权分配及发行总计 198.55万股对价股份。 药师帮(09885)发布公告，于7月8日至7月29日，根据公司于2019年1月1日采纳的2019年股份激励计划， 因行使所获授予的购股权发行合共56.04万股股份。 ...

于7月29日根据股份购买协议拟以每股对价股份12港元的发行价格，根据一般授权分配及发行总计 198.55万股对价股份。 智通财经APP讯，药师帮(09885)发布公告，于7月8日至7月29日，根据公司于2019年1月1日采纳的2019 年股份激励计划，因行使所获授予的购股权发行合共56.04万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年7月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 09885 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | ...

Summary of the Conference Call for Yaoshi Bang Company Overview - **Company**: Yaoshi Bang - **Industry**: Pharmaceutical distribution and healthcare services Key Points and Arguments Business Model and Financial Performance - Yaoshi Bang operates a self-operated model for generic drugs, achieving positive operating cash flow without the need for financing expansion. This model involves direct procurement from upstream pharmaceutical companies and sales to downstream clients, resulting in a high-frequency, small-order fulfillment system with zero accounts receivable [2][3] - The company's gross margin has reached 30%-40%, with a significant growth rate of 530% for its private label products in the first four months of the year, surpassing the total scale of the previous year [2][7] - For the first half of 2025, the company expects a net profit of 100-150 million, with an adjusted net profit of 200-250 million, indicating confidence in achieving high-end forecast targets [5] Market Dynamics and Customer Segmentation - Single pharmacies contribute approximately 60% of the company's GMV, while small and medium-sized chains and grassroots medical institutions each contribute 20% [6] - Despite a contraction in the pharmacy industry, the number of single pharmacies continues to grow, with small chains performing relatively well. The company believes that the outpatient pharmaceutical market will grow faster than the inpatient market, leading to sustained business growth [6] Inventory and Cash Flow Management - The inventory turnover days are projected to be around 30 days by the end of 2024, with actual turnover closer to 20 days. The company maintains zero accounts receivable by implementing a cash-on-delivery policy [8] - The overall expense ratio is expected to decrease from 10.7% in 2024 to 8.5% by 2028, driven by fixed cost reductions and improved management efficiency [9] Growth Strategy and Future Outlook - The company aims to achieve a gross merchandise volume (GMV) of 5 billion for its private label products by 2028, with over 90% of this coming from private labels [7] - Yaoshi Bang's self-operated business accounts for 40% of its B2P GMV, with expectations for this segment to double by 2025 [4][10] - The company is focused on increasing procurement frequency rather than average order value, with over 400,000 paying users averaging 29 purchases per month [11] Competitive Landscape - Yaoshi Bang does not face direct competition from platforms like JD and Alibaba, as they primarily target the B2C market. The company has carved out a niche in the outpatient market, which has been largely overlooked by traditional suppliers [14][15] - The company has established a strong foothold in the market, with no significant new competitors expected to emerge due to the extensive infrastructure already in place [16] Industry Trends - The large chain pharmacy sector has seen stagnation, with a chain rate of 57.8% in 2022 and 2023. In contrast, single pharmacies are thriving due to lower operational costs and a more personalized service model [18] - The company collaborates with top 100 large chains, achieving annual procurement amounts of 100-200 million, enhancing its bargaining power with suppliers [19] Future Growth Engines - The company's growth over the next three to five years will depend on industry conditions, with potential growth rates of 10-30% based on market recovery [27] - Yaoshi Bang plans to enhance service quality through proprietary brands and standardized traditional Chinese medicine products, while also promoting POCT devices to improve the operational capabilities of grassroots medical institutions [27] Valuation and Market Position - The company's current market value is considered undervalued, with a clear path for future profitability driven by a comprehensive infrastructure and digital operations [28] Additional Important Insights - The company maintains a commitment to stable dividends as long as it remains profitable, with expected net profits significantly higher than the previous year [26] - Operating cash flow is projected to continue increasing, driven by effective working capital management [24][25]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年7月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 註銷回購股份 董 事 會 進 一 步 宣 佈，截 至 本 公 告 日 期，本 公 司 已 回 購 合 共5,635,000股 股 份，佔 股份註銷（定 義 見 下 文）前本公司截至本公告日期已發行股份總數約0.8261%。 上述股份回購所用資金總額約為44,298,214港 元（不 包 括 佣 金 及 其 他 費 用）。 該等由本公司回購的股份已於2025年7月4日註銷（「股份註銷」）。因 此，本 公 司 的已發行股份總數將減少5,635,000股 至676,464,895股。 承董事會命 藥師幫股份有限公司 主席兼執行董事 張步鎮先生 香 港，2025年7月4日 於 本 公 告 日 期，董 事 會 成 員 包 ...

Core Viewpoint - The "Gelonghui Golden Award" ESG Excellence Company selection recognizes companies that excel in environmental, social, and governance dimensions, contributing to China's dual carbon goals and setting benchmarks for long-term value in the capital market [1][2]. Group 1: Award Winners - Twelve companies were awarded the "ESG Sustainable Development Excellence Enterprise" title, including Fourth Paradigm (06682.HK), JinJing New Energy (01783.HK), Kangqiao Yuelife (02205.HK), Ping An Good Doctor (01833.HK), AAC Technologies (02018.HK), Shoucheng Holdings (00697.HK), Tongwei Co., Ltd. (600438.SH), Yaoshi Bang (09885.HK), Zhaojin Mining (01818.HK), China Chunlai (01969.HK), China Reinsurance (01508.HK), and China Nuclear International (02302.HK) [1]. - The ranking of the awarded companies is in alphabetical order and does not indicate any specific order of merit [1]. Group 2: Evaluation Criteria - The selection process involved quantitative data analysis and evaluation by an expert panel to determine the final results [1]. - The award aims to highlight companies that actively promote green transformation and social responsibility through transparent governance [1]. Group 3: Scope of the Selection - The ESG Excellence Company selection covers all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [2]. - The initiative is designed to create a reference value ranking of outstanding companies in the ESG field within the investment community [2].

YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 提名委員會的職權範圍 藥師幫股份有限公司（「本公司」）根據本公司董事會（「董事會」）於2022年5月14日 通過的決議案成立提名委員會（「委員會」）。下 文 載 列 委 員 會 的 職 權 範 圍（「職 權 範 圍」）。職 權 範 圍 備 有 中 英 文 版 本 以 供 閱 覽。如 職 權 範 圍 的 中 英 文 版 本 出 現 任 何 歧 義，概 以 英 文 版 本 為 準。 1. 目 的 1.1 委 員 會 旨 在 物 色、考 慮 及 向 董 事 會 推 薦 合 適 人 選 出 任 本 公 司 董 事，監 管 評 估 董 事 會 表 現 的 程 序，制 訂 提 名 指 引 及 就 此 向 董 事 會 提 供 建 議，當 中 應 符 合 任 何 適 用 法 律、法 規 及 上 市 準 則。 2. 組 成 – 1 – 2.1 委 員 會 成 員 由 董 事 會 不 時 委 任，其 中 大 多 數 成 員 須 為 符 合《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 ...